Abstract
A role for dendritic cells (DCs) has been emphasized in the onset of acute graft-versus-host disease (GVHD). We have made efforts to develop a new strategy for suppression of DC functions with a chemical compound in the treatment of acute GVHD. We here describe the immunological characterization of the new chemical compound NK026680. It was found that NK026680 significantly suppressed (1) expression of CD83, CD86, and major histocompatibility complex (MHC) class I and II antigens on human monocyte-derived DCs, (2) excretion of interleukin-12p40 on activation of monocyte-derived DCs, (3) allogeneic responses of human and mouse T cells and (4) mortality in mice with acute GVHD evoked across MHC class I or II. The beneficial effect of NK026680 administered orally was without any recognizable adverse effects. Early intervention in acute GVHD was required for this effect, indicating that an early event in acute GVHD is a critical target of NK026680. We propose the use of NK026680 as a prophylactic for acute GVHD.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Thomson AW, Lu L . Dendritic cells as regulators of immune reactivity: implications for transplantation. Transplantation 1999; 68: 1–8.
Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412–415.
Wise MP, Bemelman F, Cobbold SP, Waldmann H . Linked suppression of skin graft rejection can operate through indirect recognition. J Immunol 1998; 161: 5813–5816.
Collin MP, Munster D, Clark G, Wang XN, Dickinson AM, Hart DN . In vitro depletion of tissue-derived dendritic cells by CMRF-44 antibody and alemtuzumab: implications for the control of graft-versus-host disease. Transplantation 2005; 79: 722–725.
Ji SQ, Chen HR, Yan HM, Wang HX, Liu J, Zhu PY et al. Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for hematological malignancies. Bone Marrow Transplant 2005; 36: 349–354.
Cahn JY, Bordigoni P, Tiberghien P, Milpied N, Brion A, Widjenes J et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Transplantation 1995; 60: 939–942.
Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999; 340: 1704–1714.
Holler E, Kolb HJ, Mittermuller J, Kaul M, Ledderose G, Duell T et al. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 1995; 86: 890–899.
Hackstein H, Thomson AW . Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 2004; 4: 24–34.
Akagawa KS, Takasuka N, Nozaki Y, Komuro I, Azuma M, Ueda M et al. Generation of CD1+RelB+ dendritic cells and tartrate-resistant acid phosphatase-positive osteoclast-like multinucleated giant cells from human monocytes. Blood 1996; 88: 4029–4039.
Geissmann F, Revy P, Regnault A, Lepelletier Y, Dy M, Brousse N et al. TGF-β1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol 1999; 162: 4567–4575.
Blazar BR, Sharpe AH, Taylor PA, Panoskaltsis-Mortari A, Gray GS, Korngold R et al. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells. J Immunol 1996; 157: 3250–3259.
Yu XZ, Martin PJ, Anasetti C . Role of CD28 in acute graft-versus-host disease. Blood 1998; 92: 2963–2970.
Steinman RM . The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271–296.
Banchereau J, Steinman RM . Dendritic cells and the control of immunity. Nature 1998; 392: 245–252.
Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J . Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001; 294: 1540–1543.
Feldmann M, Brennan FM, Maini RN . Rheumatoid arthritis. Cell 1996; 85: 307–310.
Tsark EC, Wang W, Teng YC, Arkfeld D, Dodge GR, Kovats S . Differential MHC class II-mediated presentation of rheumatoid arthritis autoantigens by human dendritic cells and macrophages. J Immunol 2002; 169: 6625–6633.
Ohshima Y, Delespesse G . T cell-derived IL-4 and dendritic cell-derived IL-12 regulate the lymphokine-producing phenotype of alloantigen-primed naive human CD4T cells. J Immunol 1997; 158: 629–636.
Schmidt CS, Mescher MF . Peptide antigen priming of naive, but not memory, CD8T cells requires a third signal that can be provided by IL-12. J Immunol 2002; 168: 5521–5529.
Murai M, Yoneyama H, Ezaki T, Suematsu M, Terashima Y, Harada A et al. Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat Immunol 2003; 4: 154–160.
Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA . Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 2001; 166: 973–981.
Acknowledgements
We thank Dr M Nose and Dr H Harigae for critical discussion, and Mrs N Fujisawa for secretarial assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Saiga, K., Toyoda, E., Tokunaka, K. et al. NK026680, a novel compound suppressive of dendritic cell function, ameliorates mortality in acute lethal graft-versus-host reaction in mice. Bone Marrow Transplant 37, 317–323 (2006). https://doi.org/10.1038/sj.bmt.1705231
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705231
Keywords
This article is cited by
-
Selective elimination of alloreactivity in vitro and in vivo while sparing other T-cell-mediated immune responses
Bone Marrow Transplantation (2012)